Safe
Harbor Statement
This presentation contains forward-looking
statements
which include, without limitation, statements
regarding the completion of the proposed merger, the mergers anticipated benefits,
timing, progress and
anticipated completion of the combined companys
clinical stage and research programs, including possible
regulatory
approval, the potential benefits that patients may experience from the use of the combined
companys clinical stage compounds, and the cash position of the combined company,
which statements are
hereby identified as forward-looking
statements
for purposes of the safe harbor provided by the Private
Securities Litigation Reform Act of 1995. Such statements are based on our
managements current
expectations and involve risks and uncertainties.
Actual results
and performance could differ materially from
those projected in the forward-looking statements as a result of many factors,
including, without limitation,
failure to complete the merger in a timely
fashion, the risk that Nuvelos and ARCAs business operations will
not be integrated successfully; the combined companys inability to further
identify, develop and achieve
commercial success for products and
technologies; the risk that the combined companys financial
resources
will be insufficient to meet the combined companys business objectives; uncertainties relating to
drug discovery and the regulatory approval process; clinical development processes;
enrollment rates for
patients in our clinical trials; changes in
relationships with strategic partners and dependence upon strategic
partners
for the performance of critical activities under collaborative agreements; and the impact of
competitive products and technological changes. These and other factors are identified
and described in
more detail in Nuvelos filings with the SEC,
including without limitation Nuvelos quarterly report on Form
10-Q
for the quarter ended June
30, 2008 and subsequent filings. We disclaim any
intent or obligation to
update these forward-looking statements
2
|